

5M2025 BUSINESS UPDATES

IMEXPHARM CORPORATION



Sustained growth trajectory in May 2025

May net revenue

VND 192 bn

▲ 34% YoY

May EBITDA

VND 41 bn

▲ 57% YoY

May PBT

VND 33 bn

▲ 97% YoY



▲ 54% YoY (*)



▲ 31% YoY (*)

(*) Gross revenue before sales deduction

- We delivered robust year-over-year growth in both revenue and profitability in May.
- ETC revenue continued to grow exceptionally, reflecting high demand of IMP's EU-GMP products.
- OTC recovered promisingly across all regions, contributing to solid performance in the month. Sales through distributors and the wholesale market achieved remarkable growth of 108% and 102%, respectively.

Strong 5M performance, on track for full-year targets

5M net revenue

VND 1,001 bn

▲ 25% YoY

5M EBITDA

VND 211 bn

▲ 23% YoY

5M PBT

VND 161 bn

▲ 34% YoY



▲ 34% YoY (*)



▲ 27% YoY (*)

(*) Gross revenue before sales deduction

- Shifting towards high-value products boosted sales value of all factories with a modest increase in sales volume of IMP1,2,3. IMP4 almost doubled its sales volume and sales value compared to 5M2024 given consistently high demand for EU-GMP injectable antibiotics.
- Profitability continued to be improved as COGS was optimized effectively.
- OTC recovered strongly with sales via chains increasing 107% year-on-year, accounting for 14% of total OTC revenue.

Business highlights

Kicked off the project of upgrading the Operational Management System through a partnership with [Base.vn](#)



Scientific seminar about cough medicine

"Common Combinations in Cough Treatment at Pharmacies," with valuable insights from leading industry experts




Stock performance & News highlights

	IMP	DHG	TRA	DHT	DBD	DMC
YTD avg. daily trading volume	231,031	25,516	4,799	40,031	331,617	10,841
YTD stock performance	▲ 11%	▼ (6%)	▼ (6%)	▼ (13%)	▼ (10)%	▼ (10%)
Daily trading volume in 5M25 vs. 5M24	▲ 636%	▲ 32%	▲ 124%	▼ (73%)	▲ 155%	▲ 270%
Market cap (VND billion)	8,008	12,813	3,047	6,801	4,865	2,153

Livzon Pharmaceutical Group announced a framework agreement to acquire 64.8% of IMP from SK and its related parties

- The prospective acquisition of a major stake in Imexpharm demonstrates an international giant's confidence in IMP's transparency, efficiency, and growth potential.
- It's expected to unlock significant opportunities for Imexpharm to access Livzon's advanced technologies, stringent quality management processes, and diverse product portfolio.



Disclaimer

The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter.

IMP is exempt from any liability for any losses and damages relating to the use of this document as well as other inaccurate, incomplete, or untimely information about IMP. IMP has the right to change and update information in our newsletters at any time without prior notice.

Contact Us

Imexpharm Investor Relations Team

Office: Floor 24, Flemington Tower, 182 Le Dai Hanh Street, Ward 15, District 11, HCMC

Email: ir@imexpharm.com



Thank You



For further discussion, please contact our IR team
ir@imexpharm.com